GAIL L BROWN, M.D.
Osteopathic Medicine at Woodside Rd, Redwood City, CA
License number
California 42880
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
2995 Woodside Rd SUITE 400, Redwood City, CA 94062
Phone
(650) 845-7901
Professional information
Gail L Brown, Woodside CA
Specialties:
Internist
Address:
2995 Woodside Rd, Woodside, CA 94062
Education:
University of Rochester, School of Medicine and Dentistry - Doctor of Medicine
Dana-Farber Cancer Institute - Fellowship - Oncology (Internal Medicine)
Brigham & Women's Hospital - Residency - Family Medicine
Dana-Farber Cancer Institute - Fellowship - Oncology (Internal Medicine)
Brigham & Women's Hospital - Residency - Family Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
Dr. Gail L Brown, Woodside CA - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
GAIL L BROWN MD
2995 Woodside Rd STE 400, Woodside 94062
(650) 845-7901 (Phone), (650) 364-9608 (Fax)
2995 Woodside Rd STE 400, Woodside 94062
(650) 845-7901 (Phone), (650) 364-9608 (Fax)
Certifications:
Internal Medicine, 1979
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
GAIL L BROWN MD
2995 Woodside Rd STE 400, Woodside 94062
Sequoia Hospital
170 Alameda De Las Pulgas, Redwood City 94062
2995 Woodside Rd STE 400, Woodside 94062
Sequoia Hospital
170 Alameda De Las Pulgas, Redwood City 94062
Education:
Medical School
University of Rochester
Graduated: 1976
Brigham and Womens Hospital
Dana-Farber Cancer Institute
University of Rochester
Graduated: 1976
Brigham and Womens Hospital
Dana-Farber Cancer Institute
Sensitization To Another Anticancer Therapy And/Or Amelioration Of A Side Effect Of Another Anticancer Therapy By Treatment With A Gst-Activated Anticancer Compound
US Patent:
2008016, Jul 10, 2008
Filed:
Oct 15, 2007
Appl. No.:
11/872662
Inventors:
Gail L. Brown - Woodside CA, US
James G. Keck - Redwood City CA, US
Michael M. Wick - Woodside CA, US
James G. Keck - Redwood City CA, US
Michael M. Wick - Woodside CA, US
International Classification:
A61K 33/24, A61K 38/05
US Classification:
424649, 514 7
Abstract:
A method of sensitizing a mammal, especially a human, to another anticancer therapy by administering a sensitizing effective amount of a GST-activated anticancer compound. A method of ameliorating a side effect of another anticancer therapy in a mammal, especially a human, by administering an ameliorating effective amount of a GST-activated anticancer compound. Pharmaceutical compositions for the methods. The GST-activated anticancer compound is preferably a compound of U.S. Pat. No. 5,556,942, and more preferably canfosfamide, especially as the hydrochloride salt.
Combination Cancer Therapy With A Gst-Activated Anticancer Compound And Another Anticancer Therapy
US Patent:
2008015, Jul 3, 2008
Filed:
Oct 15, 2007
Appl. No.:
11/872659
Inventors:
Hua Xu - Sunnyvale CA, US
Gail L. Brown - Woodside CA, US
Steven R. Schow - Redwood City CA, US
James G. Keck - Redwood City CA, US
Gail L. Brown - Woodside CA, US
Steven R. Schow - Redwood City CA, US
James G. Keck - Redwood City CA, US
International Classification:
A61K 31/664, A61K 38/20, A61K 38/21, A61K 39/395, A61K 31/704, A61P 35/00
US Classification:
424 852, 514118, 424 854, 4241411, 514 34
Abstract:
A method of combination cancer therapy in a mammal, especially a human, by administering a therapeutically effective amount of a GST-activated anticancer compound and a therapeutically effective amount of another anticancer therapy, that is, an anticancer therapy that is not a treatment with a GST- activated anticancer compound (including chemotherapy; molecular targeted therapy; biologic therapy; and radiotherapy, used as monotherapy or in combination). Pharmaceutical compositions, products, and kits for the method. The use of a GST-activated anticancer compound in the manufacture of a medicament for the method. A method of potentiating an anticancer therapy in a mammal, especially a human, comprising administering a therapeutically effective amount of a GST-activated anticancer compound to the mammal being treated with the anticancer therapy. The use of a GST-activated anticancer compound in the manufacture of a medicament for the method. The GST-activated anticancer compound is preferably a compound of U.S. Pat. No. 5,556,942, and more preferably TLK, especially as the hydrochloride salt.
Sensitization To Another Anticancer Therapy And/Or Amelioration Of A Side Effect Of Another Anitcancer Therapy By Treatment With A Gst-Activated Anticancer Compound
US Patent:
2005026, Nov 24, 2005
Filed:
May 19, 2005
Appl. No.:
11/133833
Inventors:
Gail Brown - Woodside CA, US
James Keck - Redwood City CA, US
Michael Wick - Woodside CA, US
James Keck - Redwood City CA, US
Michael Wick - Woodside CA, US
International Classification:
A61K038/05
US Classification:
514018000
Abstract:
A method of sensitizing a mammal, especially a human, to another anticancer therapy by administering a sensitizing effective amount of a GST-activated anticancer compound. A method of ameliorating a side effect of another anticancer therapy in a mammal, especially a human, by administering an ameliorating effective amount of a GST-activated anticancer compound. Pharmaceutical compositions for the methods. The GST-activated anticancer compound is preferably a compound of U.S. Pat. No. 5,556,942, and more preferably canfosfamide, especially as the hydrochloride salt.
Combination Cancer Therapy With A Gst-Activated Anticancer Compound And Another Anticancer Therapy
US Patent:
2004013, Jul 15, 2004
Filed:
Nov 14, 2003
Appl. No.:
10/714593
Inventors:
Hua Xu - Sunnyvale CA, US
Gail Brown - Woodside CA, US
Steven Schow - Redwood City CA, US
James Keck - Redwood City CA, US
Gail Brown - Woodside CA, US
Steven Schow - Redwood City CA, US
James Keck - Redwood City CA, US
Assignee:
Telik, Inc.
International Classification:
A61K038/05
US Classification:
514/018000
Abstract:
A method of combination cancer therapy in a mammal, especially a human, by administering a therapeutically effective amount of a GST-activated anticancer compound and a therapeutically effective amount of another anticancer therapy, that is, an anticancer therapy that is not a treatment with a GST-activated anticancer compound (including chemotherapy, molecular targeted therapy, biologic therapy, and radiotherapy, used as monotherapy or in combination). Pharmaceutical compositions, products, and kits for the method. The use of a GST-activated anticancer compound in the manufacture of a medicament for the method. A method of potentiating an anticancer therapy in a mammal, especially a human, comprising administering a therapeutically effective amount of a GST-activated anticancer compound to the mammal being treated with the anticancer therapy. The use of a GST-activated anticancer compound in the manufacture of a medicament for the method. The GST-activated anticancer compound is preferably a compound of U.S. Pat. No. 5,556,942, and more preferably TLK286, especially as the hydrochloride salt.
Methods For Treating Myelodysplastic Syndrome With Ezatiostat
US Patent:
2013003, Feb 7, 2013
Filed:
Apr 2, 2012
Appl. No.:
13/437474
Inventors:
Gail L. Brown - Woodside CA, US
International Classification:
A61K 31/24, A61P 7/00, C40B 30/00
US Classification:
514533, 506 7
Abstract:
This invention relates to methods, assays, devices and systems for identifying patients having a myelodysplastic syndrome for treatment with ezatiostat or a salt thereof, or evaluating the patient's response possibility to the treatment by measuring and evaluating the patient's gene expression profile. This invention also relates to methods of treating myelodysplastic syndromes.
Canfosfamide Monotherapy For Treating Multiple Myeloma
US Patent:
2012028, Nov 15, 2012
Filed:
May 12, 2011
Appl. No.:
13/106702
Inventors:
Gail L. Brown - Woodside CA, US
International Classification:
A61K 9/127, C07F 9/24, A61P 35/00, A61K 39/395, A61K 31/675, A61K 31/664, A61K 31/69
US Classification:
424450, 514118, 558171, 514 64, 4241331, 514110
Abstract:
Provided herein are methods for treating multiple myeloma by administering canfosfamide or a pharmaceutically acceptable salt thereof as a monotherapy, and also by administering canfosfamide or a pharmaceutically acceptable salt thereof as part of novel combination therapies further comprising one or more of bortezomib, lenalidomide, vorinostat, carfilzomib, pomalidomide, and elotuzumab.
Compositions And Methods For Treating Myelodysplastic Syndrome
US Patent:
2011030, Dec 8, 2011
Filed:
May 16, 2011
Appl. No.:
13/108756
Inventors:
Gail L. Brown - Woodside CA, US
Lixin Meng - Cupertino CA, US
Lixin Meng - Cupertino CA, US
International Classification:
A61K 31/454, A61P 7/00
US Classification:
514323
Abstract:
This invention generally relates to compositions and methods for treating myelodysplastic syndrome. In one embodiment, this invention relates to methods for treating myelodysplastic syndrome with ezatiostat or a salt thereof in patients who have been treated with a DNA methyltransferase inhibitor by a combination of ezatiostat or a salt thereof and lenalidomide.
Compositions And Methods For Treating Myelodysplastic Syndrome
US Patent:
2011030, Dec 8, 2011
Filed:
May 16, 2011
Appl. No.:
13/108754
Inventors:
Gail L. Brown - Woodside CA, US
Lixin Meng - Cupertino CA, US
Lixin Meng - Cupertino CA, US
International Classification:
A61K 31/225, A61P 7/00, A61K 31/454
US Classification:
514323, 514533
Abstract:
This invention generally relates to compositions and methods for treating myelodysplastic syndrome. In one embodiment, this invention relates to methods for treating myelodysplastic syndrome with ezatiostat or a salt thereof and lenalidomide.